Published in Mediators Inflamm on January 01, 1993
Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum. PLoS One (2012) 1.09
Contrasting genetic association of IL2RA with SLE and ANCA-associated vasculitis. BMC Med Genet (2009) 1.01
A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry (2016) 0.99
T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology (2010) 0.96
Microbial translocation is associated with extensive immune activation in dengue virus infected patients with severe disease. PLoS Negl Trop Dis (2013) 0.92
Serum Levels of Soluble IL-2R, CD4 and CD8 in Chronic Active HCV Positive Hepatitis. Mediators Inflamm (1994) 0.83
Cocaine alters cytokine profiles in HIV-1-infected African American individuals in the DrexelMed HIV/AIDS genetic analysis cohort. J Acquir Immune Defic Syndr (2014) 0.82
Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics. Psychopharmacology (Berl) (2008) 0.81
Serum levels of soluble IL-2R, CD4 and CD8 in bronChial asthma. Mediators Inflamm (1995) 0.80
Soluble cytokine receptors (sIL-2Rα, sIL-2Rβ) induce subunit-specific behavioral responses and accumulate in the cerebral cortex and basal forebrain. PLoS One (2012) 0.80
The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) (2006) 0.80
Serum levels of total IgE and soluble CD23 in bronchial asthma. Mediators Inflamm (1996) 0.79
Evaluation of the immunomodulatory effects of a South African commercial traditional immune booster in human peripheral blood mononuclear cells. BMC Complement Altern Med (2016) 0.78
Elevation of proinflammatory cytokines in patients with Aicardi-Goutières syndrome. Neurology (2013) 0.78
Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis. Rheumatology (Oxford) (2013) 0.77
Stress-Related Immune Markers in Depression: Implications for Treatment. Int J Neuropsychopharmacol (2016) 0.76
The Immune Effects of an African Traditional Energy Tonic in In Vitro and In Vivo Models. Evid Based Complement Alternat Med (2017) 0.75
Relationship between Serum Soluble Interleukin-2 Receptor and Renal Allograft Rejection: A Hospital-Based Study in KashmirValley. Int J Organ Transplant Med (2015) 0.75
Selected immunological parameters in clinical evaluation of patients with atopic dermatitis. Postepy Dermatol Alergol (2016) 0.75
The relationship between smoking intensity and subclinical cardiovascular injury: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis (2017) 0.75
Elevated Plasma Levels of sIL-2R in Complex Regional Pain Syndrome: A Pathogenic Role for T-Lymphocytes? Mediators Inflamm (2017) 0.75
Characterization of the Physiological Response following In Vivo Administration of Astragalus membranaceus. Evid Based Complement Alternat Med (2016) 0.75
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 31.72
Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (1976) 15.73
Interleukin-2: inception, impact, and implications. Science (1988) 8.19
Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature (1984) 7.37
Structure and expression of a cloned cDNA for human interleukin-2. Nature (1983) 7.04
The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med (1990) 6.94
Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol (1989) 5.92
Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol (1985) 5.70
Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's. Science (1989) 5.08
Molecular cloning of cDNA encoding human interleukin-2 receptor. Nature (1984) 4.95
Interleukin 2 high-affinity receptor expression requires two distinct binding proteins. J Exp Med (1987) 4.53
Cloning of the gamma chain of the human IL-2 receptor. Science (1992) 4.50
Interleukin 2. Annu Rev Immunol (1984) 4.37
Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med (1989) 4.20
Interaction of the IL-2 receptor with the src-family kinase p56lck: identification of novel intermolecular association. Science (1991) 3.84
The interleukin 2 receptor. Functional consequences of its bimolecular structure. J Exp Med (1987) 3.66
Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu Rev Immunol (1990) 3.55
The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science (1986) 3.32
Expression of interleukin 2 receptors on activated human B cells. J Exp Med (1984) 3.27
Cytokine receptors and signal transduction. Annu Rev Immunol (1992) 3.27
Cloning, sequence and expression of human interleukin-2 receptor. Nature (1985) 3.02
Characterization of the human receptor for T-cell growth factor. Proc Natl Acad Sci U S A (1983) 2.76
Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sci U S A (1983) 2.73
Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors. Proc Natl Acad Sci U S A (1987) 2.65
A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac. Hybridoma (1985) 2.41
The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science (1987) 2.35
The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med (1990) 2.34
The human interleukin-2 receptor. Annu Rev Immunol (1986) 2.29
Phenotypic expression of Hodgkin's and Reed-Sternberg cells in Hodgkin's disease. Am J Pathol (1985) 2.17
Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor. J Exp Med (1987) 2.15
Sequential measurements of soluble interleukin 2 receptor levels in plasma of heart transplant recipients. Transplantation (1990) 2.06
Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. J Immunol (1987) 1.96
The interleukin-2 receptor. J Biol Chem (1991) 1.90
Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med (1985) 1.87
Detection and functional studies of p60-65 (Tac antigen) on activated human B cells. J Exp Med (1984) 1.84
Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol (1988) 1.70
Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum (1988) 1.67
A thymocyte-activating factor derived from glomerular mesangial cells. J Immunol (1983) 1.59
Determinants of HIV disease progression: six-year longitudinal study in the Edinburgh haemophilia/HIV cohort. Lancet (1991) 1.58
Diseases associated with HTLV-I: virus, IL-2 receptor dysregulation and redox regulation. Immunol Today (1992) 1.47
Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol (1987) 1.42
Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum (1988) 1.41
Serum interleukin-2-receptor in rheumatoid arthritis: a prognostic indicator of disease activity? J Autoimmun (1988) 1.38
Plasma interleukin 2 receptor levels in renal allograft recipients. Clin Immunol Immunopathol (1987) 1.38
The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced by the human T-lymphotropic retroviruses. Ann Intern Med (1986) 1.37
Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol (1988) 1.33
Immune activation in measles. N Engl J Med (1989) 1.33
Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations. Arthritis Rheum (1990) 1.27
Soluble CD4 in patients with rheumatoid arthritis and osteoarthritis. Clin Immunol Immunopathol (1991) 1.25
Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease. Int J Clin Lab Res (1991) 1.17
Elevated soluble interleukin-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. Arthritis Rheum (1988) 1.15
Preferential expression of IL-2 receptor subunits on memory populations within CD4+ and CD8+ T cells. Immunology (1991) 1.13
Soluble CD8 in patients with rheumatic diseases. Clin Exp Immunol (1990) 1.09
Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. Br J Cancer (1987) 1.09
The production of soluble and cellular interleukin-2 receptors by cord blood mononuclear cells following in vitro activation. Pediatr Res (1986) 1.08
Serum increases and lymphoid cell surface losses of IL-2 receptor CD25 in HIV infection: distinctive parameters of HIV-induced change. Clin Immunol Immunopathol (1991) 1.08
Evolution of the levels of soluble interleukin-2 receptors during Plasmodium falciparum and P. vivax malaria. J Clin Microbiol (1989) 1.07
Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood (1988) 1.06
Serum levels of soluble IL-2 receptor, IL-4 and IgE-binding factors in childhood allergic diseases. Clin Exp Immunol (1991) 1.05
A transient rise in agalactosyl IgG correlating with free interleukin 2 receptors, during episodes of erythema nodosum leprosum. Clin Exp Immunol (1989) 1.03
Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus. Ann Rheum Dis (1989) 1.01
Immunohistological analysis of Tac antigen expression in tissues involved by Hodgkin's disease. Br J Cancer (1984) 1.00
Soluble interleukin 2 receptors are elevated in patients with AIDS or at risk of developing AIDS. Clin Immunol Immunopathol (1987) 0.99
The monocyte interleukin-2 receptor light chain: production of cell-associated and soluble interleukin-2 receptor by monocytes. Immunology (1992) 0.99
Raised serum levels of CD8, CD25 and beta 2-microglobulin in common variable immunodeficiency. Clin Exp Immunol (1991) 0.99
Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. N Engl J Med (1988) 0.99
Serum-soluble interleukin-2 receptor levels in Kawasaki disease. J Pediatr (1990) 0.97
IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. Am J Pathol (1987) 0.97
Interleukin 2 and soluble interleukin 2-receptor secretion defect in vitro in newly diagnosed type I diabetic patients. Diabetes (1989) 0.97
The human interleukin-2 receptor: a molecular and biochemical analysis of structure and function. Clin Res (1987) 0.97
Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis. Clin Exp Immunol (1990) 0.97
High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood (1987) 0.97
Increased serum soluble interleukin 2 receptor levels in patients with viral liver diseases. Hepatogastroenterology (1988) 0.96
The soluble interleukin-2 receptor in haematological disorders. Br J Haematol (1987) 0.96
Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases. Clin Immunol Immunopathol (1989) 0.95
Serum interleukin-2-receptor in coeliac disease: response to treatment and gluten challenge. Clin Exp Immunol (1989) 0.94
The significance of serum soluble IL-2 receptor as a marker for active visceral leishmaniasis in Sicilian patients. Clin Exp Immunol (1992) 0.94
Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: correlations with disease activity. J Rheumatol (1990) 0.93
Elevated titers of cell-free interleukin-2 receptor in serum and cerebrospinal fluid specimens of patients with acquired immunodeficiency syndrome. Immunol Lett (1986) 0.93
Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha. Clin Exp Immunol (1992) 0.92
Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood (1988) 0.92
Soluble IL-2-receptor and CD8 in the serum and the periparasitic granuloma of patients with alveolar echinococcosis. Eur Cytokine Netw (1992) 0.92
Increased soluble interleukin-2 receptor levels in the sera of type 1 diabetic patients. Diabetes Res (1988) 0.92
Soluble serum interleukin 2 receptor levels in leprosy patients. Clin Exp Immunol (1987) 0.91
Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. An immunohistologic study of 300 cases. Am J Pathol (1987) 0.91
The malignant B cells from B-chronic lymphocytic leukemia patients release TAC-soluble interleukin-2 receptors. Blood (1988) 0.91
Soluble interleukin-2 receptors in serum and bile of liver transplant recipients. Lancet (1989) 0.91
Soluble interleukin-2 receptor and soluble CD8 antigen in active rheumatoid arthritis. Clin Immunol Immunopathol (1990) 0.91
Increased in vitro release of soluble interleukin 2 receptor by colonic lamina propria mononuclear cells in inflammatory bowel disease. Gut (1992) 0.90
Increase of serum interleukin 2 receptor level in thermally injured patients. Clin Immunol Immunopathol (1989) 0.90
Prolonged elevations of soluble interleukin-2 receptors in tuberculosis. Am Rev Respir Dis (1989) 0.89
Interleukin-2, autotolerance, and autoimmunity. Adv Immunol (1991) 0.89
Serum interleukin 2 receptor levels in childhood acute lymphoblastic leukemia. Blood (1988) 0.89
Effects of alpha-interferon and prednisone on serum-soluble interleukin-2 receptor (sIL-2R) in chronic hepatitis B infection. Am J Gastroenterol (1992) 0.88
Immune dysfunction in multiple myeloma. Reduced natural killer cell activity and increased levels of soluble interleukin-2 receptors. APMIS (1991) 0.88
The biological significance of soluble interleukin-2 receptors in solid tumors. Eur J Cancer (1990) 0.88
Genotype frequencies of the +874T-->A single nucleotide polymorphism in the first intron of the interferon-gamma gene in a sample of Sicilian patients affected by tuberculosis. Eur J Immunogenet (2002) 1.38
Gender-specific association between -1082 IL-10 promoter polymorphism and longevity. Genes Immun (2002) 1.28
Inflammation, genetics, and longevity: further studies on the protective effects in men of IL-10 -1082 promoter SNP and its interaction with TNF-alpha -308 promoter SNP. J Med Genet (2003) 1.26
Age-related inflammation: the contribution of different organs, tissues and systems. How to face it for therapeutic approaches. Curr Pharm Des (2010) 1.17
In vitro cytokine production by HLA-B8,DR3 positive subjects. Autoimmunity (1994) 1.05
Opposite effects of interleukin 10 common gene polymorphisms in cardiovascular diseases and in successful ageing: genetic background of male centenarians is protective against coronary heart disease. J Med Genet (2004) 1.04
Cytokine production pathway in the elderly. Immunol Res (1996) 1.00
A genetically determined high setting of TNF-alpha influences immunologic parameters of HLA-B8,DR3 positive subjects: implications for autoimmunity. Hum Immunol (2001) 0.99
Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy (2004) 0.99
Interleukin 2 and soluble interleukin 2-receptor secretion defect in vitro in newly diagnosed type I diabetic patients. Diabetes (1989) 0.97
HLA, aging, and longevity: a critical reappraisal. Hum Immunol (2000) 0.96
Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease. Genes Immun (2003) 0.96
Measurement of inflammatory mediators of mast cells and eosinophils in native nasal lavage fluid in nasal polyposis. Int Arch Allergy Immunol (2001) 0.96
Immunogenetics of longevity. Is major histocompatibility complex polymorphism relevant to the control of human longevity? A review of literature data. Mech Ageing Dev (2001) 0.94
Association between the polymorphisms of TLR4 and CD14 genes and Alzheimer's disease. Curr Pharm Des (2008) 0.92
Major histocompatibility complex regulation of cytokine production. J Interferon Cytokine Res (1996) 0.92
Non-specific airway hyperresponsiveness in mono-sensitive Sicilian patients with allergic rhinitis. Its relationship to total serum IgE levels and blood eosinophils during and out of the pollen season. Clin Exp Allergy (1997) 0.91
B cells compartment in centenarian offspring and old people. Curr Pharm Des (2010) 0.91
A pilot study on prostate cancer risk and pro-inflammatory genotypes: pathophysiology and therapeutic implications. Curr Pharm Des (2010) 0.90
Association between the MHC class I gene HFE polymorphisms and longevity: a study in Sicilian population. Genes Immun (2002) 0.90
Association between platelet endothelial cellular adhesion molecule 1 (PECAM-1/CD31) polymorphisms and acute myocardial infarction: a study in patients from Sicily. Eur J Immunogenet (2004) 0.90
gamma-Interferon, interleukin-4 and interleukin-6 in vitro production in old subjects. Autoimmunity (1993) 0.89
Effects of in vitro treatment with fluticasone propionate on natural killer and lymphokine-induced killer activity in asthmatic and healthy individuals. Allergy (2001) 0.88
Granulocyte and natural killer activity in the elderly. Mech Ageing Dev (1999) 0.87
Analysis of hemochromatosis gene mutations in the Sicilian population: implications for survival and longevity. Arch Gerontol Geriatr Suppl (2002) 0.86
Role of TLR4 receptor polymorphisms in Boutonneuse fever. Int J Immunopathol Pharmacol (2006) 0.86
Role of genetic polymorphisms in myocardial infarction at young age. Clin Hemorheol Microcirc (2010) 0.86
Serum levels of soluble CD23 in patients with asthma or rhinitis monosensitive to Parietaria. Its relation to total serum IgE levels and eosinophil cationic protein during and out of the pollen season. Allergy Asthma Proc (1999) 0.85
Immune-inflammatory responses and oxidative stress in Alzheimer's disease: therapeutic implications. Curr Pharm Des (2010) 0.85
Age-related changes in the expression of CD95 (APO1/FAS) on blood lymphocytes. Exp Gerontol (1999) 0.83
Serum Levels of Soluble IL-2R, CD4 and CD8 in Chronic Active HCV Positive Hepatitis. Mediators Inflamm (1994) 0.83
A scientific approach to anti-ageing therapies: state of the art. Curr Pharm Des (2008) 0.83
Blood antiphospholipid antibody levels are influenced by age, sex and HLA-B8,DR3 phenotype. Exp Clin Immunogenet (1992) 0.83
Interleukin-12 release by mitogen-stimulated mononuclear cells in the elderly. Mech Ageing Dev (1998) 0.82
Early activation of gammadelta T lymphocytes in the elderly. Mech Ageing Dev (2000) 0.82
Allergic rhinitis to grass pollen: measurement of inflammatory mediators of mast cell and eosinophils in native nasal fluid lavage and in serum out of and during pollen season. J Allergy Clin Immunol (1997) 0.82
Risk profiles in type 2 diabetes (metabolic syndrome): integration of IL-10 polymorphisms and laboratory parameters to identify vascular damages related complications. Curr Pharm Des (2010) 0.82
The effect of cyclosporin A, FK506 and rapamycin on the murine contact sensitivity reaction. Clin Exp Immunol (1998) 0.81
T-cell activation in HLA-B8, DR3-positive individuals. Early antigen expression defect in vitro. Hum Immunol (1995) 0.81
Comparison of the effects of fluticasone propionate, aqueous nasal spray and levocabastine on inflammatory cells in nasal lavage and clinical activity during the pollen season in seasonal rhinitics. Clin Exp Allergy (1999) 0.81
Serum levels of soluble IL-2R, CD4 and CD8 in bronChial asthma. Mediators Inflamm (1995) 0.80
Dissociated production of interleukin-2 and immune gamma-interferon by phytohaemoagglutinin stimulated peripheral mononuclear cells in type 1 (insulin-dependent) diabetes. J Clin Lab Immunol (1988) 0.80
Soluble interleukin-2 receptor secretion defect in vitro in HLA-B8, DR3 positive subjects. Autoimmunity (1990) 0.80
Modification of cytokine patterns in subjects bearing the HLA-B8,DR3 phenotype: implications for autoimmunity. Cytokines Cell Mol Ther (1997) 0.79
HLA-B8,DR3 phenotype and the antibody response against Epstein-Barr virus. Immunol Invest (1993) 0.79
Serum levels of total IgE and soluble CD23 in bronchial asthma. Mediators Inflamm (1996) 0.79
HLA-B8,DR3 haplotype affects lymphocyte blood levels. Immunol Invest (1997) 0.79
Polyphenols from red wine modulate immune responsiveness: biological and clinical significance. Curr Pharm Des (2008) 0.79
Natural killer and lymphokine-activated killer activity in HLA-B8,DR3-positive subjects. Hum Immunol (1993) 0.78
Age- and gender-related values of lymphocyte subsets in subjects from Northern and Southern Italy. Arch Gerontol Geriatr Suppl (2002) 0.78
In vitro treatment with interleukin-2 normalizes type-1 cytokine production by lymphocytes from elderly. Immunopharmacol Immunotoxicol (2000) 0.78
The effect of age on mitogen responsive T cell precursors in human beings is completely restored by interleukin-2. Mech Ageing Dev (1992) 0.78
Biological basis of the HLA-B8,DR3-associated progression of acquired immune deficiency syndrome. Pathobiology (1998) 0.78
Apoptosis and ageing. Mech Ageing Dev (1998) 0.77
Interleukin-5 production by mononuclear cells from aged individuals: implication for autoimmunity. Mech Ageing Dev (1999) 0.77
Administration of a synbiotic to free-living elderly and evaluation of serum cytokines. A pilot study. Curr Pharm Des (2010) 0.77
Impact of different texture of polypropylene mesh on the inflammatory response. Int J Immunopathol Pharmacol (2008) 0.77
Defective expression of CD95 (FAS/APO-1) molecule suggests apoptosis impairment of T and B cells in HLA-B8, DR3-positive individuals. Hum Immunol (1997) 0.76
Soluble interleukin-2 receptor in vitro production by mononuclear cells from Hodgkin patients. Boll Ist Sieroter Milan (1990) 0.76
Soluble interleukin-2 receptor release defect in vitro in elderly subjects. Mech Ageing Dev (1991) 0.76
Pro-inflammatory gene variants in myocardial infarction and longevity: implications for pharmacogenomics. Curr Pharm Des (2008) 0.76
MHC-linked genetic factors (HLA-B35) influencing recurrent circumoral herpetic lesions. Dis Markers (1987) 0.76
Markers of T lymphocyte activation in HLA-B8, DR3 positive individuals. Immunobiology (1990) 0.76
HLA-DR3 and immunoresponsiveness. Lancet (1990) 0.75
In vitro T cell activation in elderly individuals: failure in CD69 and CD71 expression. Mech Ageing Dev (1996) 0.75
Blood eosinophils and serum eosinophil cationic protein in patients with acute and chronic urticaria. Mediators Inflamm (1996) 0.75
Whole body irradiation induces IFN-gamma production in BALB/c mice by preventing the appearance of a V alpha 14(+)NK T downregulatory population. Cytokine (2000) 0.75
In vitro thymopentin modulation of mitogen responsive T-cell precursor frequency. Thymus (1991) 0.75
HLA-DR-linked genes are involved in the control of T lymphocyte blood levels. Clin Immunol Immunopathol (1987) 0.75
HLA antigens in Sicilian patients affected by chronic myelogenous leukaemia. J Immunogenet (1987) 0.75
HLA-Cw4 association with acute lymphoblastic leukaemia in Sicilian patients. Vox Sang (1988) 0.75
HLA-DR1 and HLA-DR3 phenotypes and insulin antibody production in diabetic Sicilian patients. Exp Clin Immunogenet (1988) 0.75